GRTXD · Galera Therapeutics, Inc.
$18.99
At close · Aug 3
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, it expects its existing cash and cash equivalents as of March 31, 2026 will not enable the Company to fund its operating expenses and capital expenditure requirements for more than one year after the date these consolidated financial statements are issued, and therefore management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$3.05B
Shares
160.43M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $747,821 |
| Joel Sussman | Chief Accounting Officer, Treasurer and Secretary | $408,114 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $633,279 |
| Joel Sussman | Chief Accounting Officer, Treasurer and Secretary | $349,440 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $1,361,448 |
| Christopher Degnan | Chief Financial Officer | $834,865 |
| Mark Bachleda | Pharm.D., Chief Commercial Officer | $788,626 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $2,534,676 |
| Mark Bachleda | Pharm.D., Chief Commercial Officer | $1,288,415 |
| Christopher Degnan | Chief Financial Officer | $1,273,545 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $2,958,232 |
| Christopher Degnan | Chief Financial Officer | $1,458,593 |
| Robert A. Beardsley | Ph.D., Chief Operating Officer | $1,449,913 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $2,465,102 |
| Christopher Degnan | Chief Financial Officer | $2,229,086 |
| Robert A. Beardsley | Ph.D., Chief Operating Officer | $1,668,213 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| J. Mel Sorensen | M.D., President and Chief Executive Officer | $521,624 |
| Robert A. Beardsley | Ph.D., Chief Operating Officer | $423,405 |
| Christopher Degnan | Chief Financial Officer | — |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Christopher Degnan | Chief Financial Officer and principal financial officer | Terminated | 2024-08-14 |
| Robert A. Beardsley | Chief Operating Officer | Terminated | 2024-06-07 |
| Mark Bachleda | Chief Commercial Officer | Terminated | 2023-08-10 |